Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q8TAC2
UPID:
JOS2_HUMAN
Alternative names:
Josephin domain-containing protein 2
Alternative UPACC:
Q8TAC2; M0QX25
Background:
Josephin-2, also known as Josephin domain-containing protein 2, plays a crucial role in cellular processes through its ability to cleave 'Lys-63'-linked poly-ubiquitin chains, and to a lesser extent 'Lys-48'-linked poly-ubiquitin chains. This specificity suggests a unique function in ubiquitin-mediated signaling pathways.
Therapeutic significance:
Understanding the role of Josephin-2 could open doors to potential therapeutic strategies. Its activity in modulating ubiquitin chains hints at its importance in cellular regulation and disease mechanisms.